Holen Sie sich die Stockscreener-App
32.96
7.43%
2.28
Schlusskurs vom Vortag:
$30.68
Offen:
$32.58
24-Stunden-Volumen:
1,298
Relative Volume:
0.17
Marktkapitalisierung:
$3.06B
Einnahmen:
$136.33M
Nettoeinkommen (Verlust:
$-56.34M
KGV:
-43.92
EPS:
-0.7504
Netto-Cashflow:
$-18.87M
1W Leistung:
+1.42%
1M Leistung:
+0.15%
6M Leistung:
+17.84%
1J Leistung:
+0.00%
1-Tages-Spanne:
$32.58
$32.96
1-Wochen-Bereich:
$30.00
$33.09
52-Wochen-Spanne:
$17.09
$48.45
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Firmenname
Ascentage Pharma Group International Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie AAPG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
32.96 | 2.85B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.61 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.50 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
459.15 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
900.90 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.34 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-10 | Eingeleitet | BTIG Research | Buy |
| 2025-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-27 | Eingeleitet | JP Morgan | Overweight |
Ascentage Pharma Group International Adr Aktie (AAPG) Neueste Nachrichten
Cash per share of Ascentage Pharma Group International Unsponsored ADR – LS:A40ZYR - TradingView
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA - GlobeNewswire Inc.
ETFs Investing in Ascentage Pharma Group International Unsponsored ADR Stocks - TradingView
Ascentage Pharma to Highlight Key Data from ASH 2025 in Upcoming Webcast - TipRanks
Ascentage Pharma Announces New RSU and Share Option Grants - TipRanks
Analysts’ Top Healthcare Picks: Amgen (AMGN), Opus Genetics (IRD) - The Globe and Mail
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Now Covered by Analysts at Truist Financial - Defense World
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownHere's What Happened - MarketBeat
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Today | Live Chart & News - Traders Union
Ascentage Pharma Group International ADR (AAPG) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 12.2%Should You Sell? - MarketBeat
Ascentage Pharma to Engage Investors at December 2025 Conferences - TipRanks
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), NeurAxis, Inc. (NRXS) and Celcuity (CELC) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: AMN Healthcare Services (AMN) and Crispr Therapeutics AG (CRSP) - The Globe and Mail
Promising Potential of Ascentage Pharma’s Key Assets: Olverembatinib and Lisaftoclax Drive Buy Rating Amidst Risks - TipRanks
Free cash flow per share of Ascentage Pharma Group International Unsponsored ADR – SWB:36X0 - TradingView
Ascentage Pharma to Engage Investors at November Conferences - TipRanks
Centurion Acquisition Corp. (NASDAQ:ALFUW) Short Interest Down 57.1% in October - Defense World
Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Short Interest Down 82.7% in October - MarketBeat
Zymeworks’ Promising FRa ADC Potential: Buy Rating Affirmed by Analyst - TipRanks
Revolution Medicines: Strong Buy Rating Driven by Innovative Oncology Advancements and Strategic Market Position - TipRanks
Promising Early-Stage Data and Competitive Positioning Support Buy Rating for Zymeworks’ ADC Platform - TipRanks
Allogene Therapeutics (ALLO) was downgraded to a Sell Rating at J.P. Morgan - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Trading Up 3.5%Here's What Happened - MarketBeat
J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV) - The Globe and Mail
Ascentage Pharma Engages Investors at October 2025 Conferences - TipRanks
Ascentage Pharma Group International (OTCMKTS:ASPHF) Short Interest Up 70.0% in September - Defense World
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 4.5%Here's What Happened - MarketBeat
Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat
Here's Why Ascentage Pharma Group InternationalUnsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Ascentage Pharma to Engage with Investors at September Conferences - TipRanks
Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 52-Week High – Should You Buy? - Defense World
Ascentage Pharma to Announce 2025 Interim Results and Corporate Update - The Globe and Mail
Ascentage Pharma to Engage in Evercore China Biotech Summit - TipRanks
Ascentage Pharma Completes Offshore Placement to Boost Global Operations - TipRanks
Ascentage Pharma Group International – Unsponsored ADR’s (NASDAQ:AAPG) Lock-Up Period Set To End on July 23rd - Defense World
Finanzdaten der Ascentage Pharma Group International Adr-Aktie (AAPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):